# ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

> **NCT05629702** · PHASE2 · RECRUITING · sponsor: **University of Birmingham** · enrollment: 120 (estimated)

## Conditions studied

- Glioblastoma
- Brain Tumor
- Cannabis
- Brain Tumor, Recurrent

## Interventions

- **DRUG:** Nabiximols
- **DRUG:** Temozolomide
- **DRUG:** Nabiximols-matched placebo

## Key facts

- **NCT ID:** NCT05629702
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-03
- **Primary completion:** 2026-09
- **Final completion:** 2027-04
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629702, "ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05629702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*